MediWound – a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair – recently announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC) has awarded MediWound an additional $6.7 million in non-dilutive funding for developing NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army.
This $14.4 million project budget will advance the development and production of a new temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.
Vericel Corporation holds an exclusive license encompassing the commercial and development rights to NexoBrid in North America as outlined in the license agreement between the company and Vericel.
The MTEC Research Project Award was granted by the DoD’s U.S. Army Medical Research and Development Command (USAMRDC) and funded by the Defense Health Agency through MTEC, a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational. And in alignment with this mission, it’s vital to have field solutions for severe burn treatments that are both easy to use and effective. Such solutions should be applicable immediately post-injury and demand minimal preparation and training.
The U.S. Army Medical Research and Development Command is the Army’s medical material developer, responsible for medical research, development, and acquisition. And USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical, and biological defense.
KEY QUOTE:
“We are delighted to further solidify our partnership with the U.S. Department of Defense. The additional funding will enhance our CMC activities, expedite preclinical development, and facilitate the establishment of a GMP compliant aseptic production line for the temperature-stable formulation of NexoBrid. This new award underscores our shared commitment to ensuring NexoBrid’s availability for military use and its potential to significantly change the early treatment approach for severe burns.”
- Ofer Gonen, Chief Executive Officer of MediWound
